Eli Lilly every day ORorglipron obesity pill seems to be equally good in stimulating body weight loss and lowering diabetic levels in diabetes patients, such as popular GLP-1 drugs, such as ozempic, in accordance with modern data from phase 3 testing. The results were announced today at the annual American Diabetes Association and Association I published At the Fresh England Journal of Medicine.
Eli Lilly is a producer of the hit of the GLP-1 drug, approved as Mounjaro for type 2 and Zepbound diabetes for chronic weight management and obstructive sleep apnea. Like Ozempic and Wegova Novo Nordisk, both Astepatide drugs Eli Lilly are injected every week. But some patients are afraid of needles or prefer to download the pill with convenience.
“We see that the effectiveness, security and tolerance are really in line with the best injected GLP-1,” says Kenneth Custer, president of Cariometbabbolic Health at Eli Lilly from the company’s experimental pill. “We think it’s a big deal.” The company plans to apply for the approval of regulatory bodies in the field of weight management by the end of this year and treatment of type 2 diabetes in 2026.
In a 40-week study, it tested three doses of orforgliprons-3 milligrams, 12 milligrams and 36 million placebo in 559 patients with type 2 diabetes. All three doses were effective in lowering blood sugar levels, while the middle and highest doses showed clinically significant and statistically significant reduction in body weight. The highest dose of orforglipron led to an average weight loss of 7.9 percent, i.e. 16 pounds – unparalleled in relation to the loss of weight observed in the same period in the study of semaglutide and girl. Eli Lilly is studying a pill in longer studies in overweight people or have obesity to see if weight loss continues.
In the current study, participants took a pill once a day without food or water restrictions. Those who were randomly assigned to Orforglipron began an examination at a dose of 1 milligram per day and slowly increased the dose at four -week intervals. Current GLP-1 drugs are gradually accelerated at the dose to minimize potential side effects.
Orforglipron showed similar side effects of the gastrointestinal tract as other GLP-1 drugs, with diarrhea, nausea, indigestion and constipation. From 4 to 8 percent of participants in various dosage groups dropped due to side effects, while 1 percent in the placebo group interrupted the study.
The oral version of the semaglutide, sold under the Rybelsus brand, has been on the market since 2019, but is not approved for weight management and is not as effective in terms of weight loss as for injecting GLP-1. The pill especially for obesity would give patients more treatment options and would potentially make these drugs more accessible.
The tablets are usually cheaper to produce and can be made more easily, which makes them less susceptible to deficiency. (Injected GLP-1 drugs were missing until recently.) Tablets can also be transported more easily. Current GLP-1 injectors must be sent and stored in the fridge to maintain their strength. The GLP-1 pill would not need a sophisticated distribution and storage of a cool chain, which means that it can be sold in countries that do not have such infrastructure.
“Since Orforglipron offers additional advantages, such as the elimination of strict preliminary requirements, potential lower costs and easier storage, it will be important that these features lead to even greater compliance,” says Priya Jaisinghani, a specialist in Medicine at NYU Langone. “Like most chronic therapies, GLP-1 is the most effective when used consistently, so the wording that encourages long-term use can have a significant impact on patients’ results.”